Clear All
760 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J3121 Testosterone Enanthate Testosterone Enanthate 1 mg Hormonal Therapy Androgen No 1953 Jan 1, 2015 In Use
Q5126 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Nov 28, 2022 In Use
J9181 Etoposide Toposar, Etopophos 10 mg Chemotherapy Plant Alkaloid Epipodophyllotoxins No 1983 Jan 1, 1987 In Use
J2405 Ondansetron Zofran, Zofran ODT, Zuplenz 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1991 Jan 1, 1993 In Use
Q2041 Axicabtagene Ciloleucel Yescarta Up to 200 million Immunotherapy CAR-T CD19 No 2017 Jan 1, 2019 In Use
J2425 Palifermin Kepivance 50 mcg Ancillary Therapy Epithelial Growth Factor Keratinocyte Growth Factor/rHuKGF No 2004 Jan 1, 2006 In Use
C9476 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jul 1, 2016 In Use
J9020 Asparaginase Erwinaze 10, 000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 1994 Jan 1, 1984 In Use
C9142 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Sep 27, 2022 Dec 21, 2022 No Longer Used
J9059 Bendamustine (Baxter) Bendamustine (Baxter) 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2022 Jul 11, 2023 Dec 17, 2024 No Longer Used
J9054 Bortezomib (boruzu) Boruzu 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2024 Mar 26, 2025 In Use
J9048 Bortezomib (Fresniuskab) Bortezomib (Fresniuskab) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2017 Dec 21, 2022 In Use
J9001 Doxorubicin Doxil 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1995 Jan 1, 2000 Dec 31, 2012 No Longer Used
J1440 Filgrastim Neupogen, Zarxio 300 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 1991 Jan 1, 2014 Dec 31, 2013 No Longer Used
J1952 Leuprolide Mesylate Camcevi 1mg Hormonal Therapy GnRH Agonist No 2021 Jan 26, 2022 In Use
Q5118 Bevacizumab-bvzr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct 1, 2019 In Use
J9219 Leuprolide Acetate Implant Viadur 65 mg Hormonal Therapy GnRH Agonist No 2000 Jan 1, 2016 In Use
Q2058 Obecabtagene autoleucel AUCATZYL up to 400 million Immunotherapy CAR-T CD-19 No 2024 Jul 9, 2025 In Use
J9360 Vinblastine Oncovin, Vincasar PFS 1 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1965 Jan 1, 1986 In Use
J9307 Pralatrexate Folotyn 1 mg Chemotherapy Antimetabolite Folic Acid Analog No 2009 Jan 1, 2011 In Use
J9063 Mirvetuximab soravtansine Elahere 1mg Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 No 2022 Jul 11, 2023 In Use
J9329 Tislelizumab-jsgr Tevimbra 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2024 Sep 11, 2024 In Use
Not yet assigned Inotuzumab Ozogamicin Besponsa 0.9 mg Immunotherapy Drug Antibody Conjugate CD22 No 2017 In Use
J1448 Trilaciclib Cosela 1mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 No 2021 Sep 27, 2021 In Use
J9032 Belinostat Beleodaq 10 mg Chemotherapy Enzyme Inhibitor HDAC No 2014 Jan 1, 2016 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.